What Picard Medical, Inc. does.

Picard Medical, Inc. ("PMI") was incorporated in the state of Delaware on April 8, 2021. Unless the context requires otherwise, in this Annual Report, the terms "we," "us," "our," the "Company," "Picard," the "Registrant," and similar references refer to the combined operations of PMI and its consolidated subsidiaries and affiliates, including SynCardia Systems, LLC ("SynCardia").

PMI functions as a holding company and owns 100% of the membership interests of SynCardia. Business operations are carried out by and through SynCardia, and accordingly most of the information in this Annual Report pertains to SynCardia's business. SynCardia is a medical technology company that manufactures and sells the only U.S. Food and Drug Administration ("FDA") and Health Canada approved Total Artificial Heart ("TAH"), which fully replaces the function of a failing human heart. To date, more than 2,100 SynCardia TAHs have been implanted in patients across 27 countries, and the SynCardia TAH is an established bridge to heart transplantation ("BTT") for patients with biventricular heart failure, also referred to as end-stage heart failure, in the United States and around the globe. SynCardia is also pursuing additional research and advancements in medical technology, including the next-generation, fully implantable and driver-less heart, the Emperor TAH. Both the SynCardia and Emperor TAH are subject to additional development and regulatory review.

Revenue and profit, by fiscal year.

More on PMI.

• Picard Medical, Inc. summary
• Picard Medical, Inc. financial statements
• Picard Medical, Inc. key metrics
• Picard Medical, Inc. health scores and style box
• Picard Medical, Inc. earnings
• Picard Medical, Inc. dividends
• Picard Medical, Inc. valuation
• Picard Medical, Inc. ownership and insiders
• Picard Medical, Inc. peers

Figures from Picard Medical, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.